Advanced Viral Research granted rheumatoid arthritis patent

By Elaine Rigoli

Tampa, Fla., July 17 - Advanced Viral Research Corp. said Monday the company received U.S. patent approval effective June 27 for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation.

Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens.

This illness affects about 1% of the world's population, according to a news release.

This patent approval comes at a time when the treatment options for rheumatoid arthritis have been limited significantly by the withdrawal of Cox 2 inhibitors from the market, officials noted.

Advanced Viral Research, based in Yonkers, N.Y., is a biopharmaceutical firm developing therapies for viral and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.